Search explainers, questions, and medicine profiles.
Research, perspective, and useful questions on this topic.
Tirzepatide’s evidence spans weight management and selected health outcomes; brand, country, and study population still matter.
Survodutide has new Phase 3 obesity evidence, including a diabetes trial. It remains separate from an approved prescription and from liver-disease outcomes.
Retatrutide now has peer-reviewed Phase 3 results, but strong trial findings and routine regulatory approval remain different milestones.
Separate semaglutide’s product-specific approvals from the weight-loss and cardiovascular trials that support particular uses.
The cagrilintide–semaglutide combination has Phase 3 evidence. Its analysis, study population, and regulatory status need separate labels.
A clear guide to appetite pathways, approved products, trial evidence, and the questions that matter before treatment.
Orforglipron is now FDA-approved as Foundayo for adult weight management; oral delivery does not remove the need for safety review.
